Sugi Predict

Sugi Predict / Targets / FGFR2

FGFR2

Fibroblast growth factor receptor 2 · P21802 · FGFR2 on Sugi Atlas →

134,489 patent compounds predicted against FGFR2, 87,674 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Pd-173074 Pd-173074 (SCHEMBL177946) 1.00 16/20
SCHEMBL63964 SCHEMBL63964 0.62 15/20
SCHEMBL62513 SCHEMBL62513 0.58 15/20
SCHEMBL63830 SCHEMBL63830 0.51 15/20
SCHEMBL63636 SCHEMBL63636 0.61 14/20
SCHEMBL63264 SCHEMBL63264 0.54 14/20
SCHEMBL64066 SCHEMBL64066 0.53 14/20
SCHEMBL62562 SCHEMBL62562 0.61 13/20
SCHEMBL63624 SCHEMBL63624 0.57 13/20
SCHEMBL62894 SCHEMBL62894 0.54 13/20
SCHEMBL63675 SCHEMBL63675 0.51 13/20
SCHEMBL63028 SCHEMBL63028 0.51 13/20
SCHEMBL63000 SCHEMBL63000 0.61 11/20
SCHEMBL63470 SCHEMBL63470 0.58 11/20
SCHEMBL143675 SCHEMBL143675 1.00 9/20
SCHEMBL144665 SCHEMBL144665 1.00 9/20
SCHEMBL147279 SCHEMBL147279 1.00 9/20
SCHEMBL116925 SCHEMBL116925 0.73 9/20
SCHEMBL146452 SCHEMBL146452 0.72 9/20
SCHEMBL63195 SCHEMBL63195 0.57 9/20

Clinical trials — most relevant to FGFR2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Dovitinib(TKI258) in Patients With Castration-resistant Prostate Cancer PHASE2COMPLETED
Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors PHASE2WITHDRAWN
A Single-Arm Phase II Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy PHASE2UNKNOWN
Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients PHASE2ENROLLING_BY_INVITATION
Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma PHASE2COMPLETED
A Study of TAS-120 in Patients With Advanced Solid Tumors PHASE1/PHASE2COMPLETED
Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling PHASE2WITHDRAWN
Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial PHASE2ACTIVE_NOT_RECRUITING
Efficacy of Pemigatinib in Patients With Solid Tumors Characterized by an Alteration of the Gene FGFR in Tumor Cells PHASE2RECRUITING
Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations PHASE2UNKNOWN
A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma PHASE2COMPLETED
Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer PHASE2UNKNOWN
Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations PHASE1/PHASE2COMPLETED
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors PHASE2ACTIVE_NOT_RECRUITING
A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201) PHASE2COMPLETED
Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma PHASE2NOT_YET_RECRUITING
Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations PHASE2COMPLETED
Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens PHASE2COMPLETED
Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations PHASE2WITHDRAWN
Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202) PHASE2COMPLETED
Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma PHASE2COMPLETED
Fulvestrant Plus Anlotinib in HR(+)/HER2(-) Metastatic Breast Cancer With FGFR Mutation PHASE2UNKNOWN
Fibroblast Growth Factor (FGFs) / Fibroblast Growth Factor Receptor (FGFRs) Genetic as a Second-line Therapy for Recurrent / Progressive Gastric Cancer With INCB054828 and Paclitaxel a Study to Evaluate the Safety and Efficacy of Combination Therapy. PHASE1/PHASE2COMPLETED
A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations PHASE2UNKNOWN
A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102) PHASE1COMPLETED
Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations PHASE1RECRUITING
Phase 1 Study of E7090 in Subjects With Solid Tumor PHASE1COMPLETED
Role of FGF21 in Breast Cancer nanNOT_YET_RECRUITING
Erdafitinib in Metastatic Steroid-cell Ovarian Cancer nanCOMPLETED
Effect of Shock Wave Therapy Without Biological and Immuno-histochemical Analysis. nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a FGFR2 binder may also engage these)

ProteinNameSimilarity
P18461 — 1.000 P18461 →
Q9I8X3 — 1.000 Q9I8X3 →
Q91147 — 1.000 Q91147 →
Q04589 — 1.000 Q04589 →
Q8JG38 — 1.000 Q8JG38 →
Q90Z00 — 1.000 Q90Z00 →
Q91287 — 1.000 Q91287 →
P21803 — 0.999 P21803 →
FGFR3 Fibroblast growth factor receptor 3 0.999 landscape →
FGFR1 Fibroblast growth factor receptor 1 0.998 landscape →
P16092 — 0.998 P16092 →
O42127 — 0.998 O42127 →
P18460 — 0.995 P18460 →
P21804 — 0.994 P21804 →
Q90330 — 0.994 Q90330 →
Q91288 — 0.994 Q91288 →
Q03364 — 0.994 Q03364 →
Q91286 — 0.994 Q91286 →
Q91743 — 0.993 Q91743 →
Q90413 — 0.990 Q90413 →
Q91285 — 0.989 Q91285 →
P22182 — 0.989 P22182 →
B4KPU0 — 0.989 B4KPU0 →
PTK2 Focal adhesion kinase 1 0.988 landscape →
EPHA5 Ephrin type-A receptor 5 0.988 landscape →
Q61851 — 0.988 Q61851 →
Q07407 — 0.988 Q07407 →
Q61083 — 0.987 Q61083 →
Q78EA7 — 0.987 Q78EA7 →
Q62838 — 0.986 Q62838 →